A Phase 1 Open-Label, Multiple Dose, Dose Escalation Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma.

Trial Profile

A Phase 1 Open-Label, Multiple Dose, Dose Escalation Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2013

At a glance

  • Drugs Dalantercept (Primary)
  • Indications Multiple myeloma; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 26 Sep 2012 Planned End Date changed from 1 Aug 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
    • 18 Jun 2012 Planned End Date changed from 1 Oct 2011 to 1 Aug 2012 as reported by ClinicalTrials.gov.
    • 13 Jun 2011 Planned end date changed from 1 May 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top